Kenneth J. Smith, MD, MS

After the FDA warning and removal of rosiglitazone from the VA National Formulary, glucose control may have declined among those discontinuing rosiglitazone without receiving replacement medication.

In Medicare Part D, generic drug coverage was cost saving compared with no coverage in bipolar disorder and schizophrenia while improving health outcomes.

To set priorities for quality improvement in trauma triage, we compared the cost-effectiveness of current practice with interventions to improve physician adherence to clinical guidelines.

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

Routine preoperative MRSA screening of cardiac surgery patients could provide substantial economic value to third-party payers and hospitals under a wide range of circumstances.

Pneumococcal polysaccharide vaccination of healthcare workers during an influenza pandemic is cost-effective from a societal perspective but not from a hospital perspective without external subsidy.

Vaccinating children earlier (ie, September or October) can provide net economic benefit to society and to third-party payers. Vaccination of children remained cost-effective through December.